Taysha Gene Therapies, Inc. (TSHA) Stock
TSHA has an Alpha Score of 22 out of 100 (poor), computed on Nov 10, 2026 from 2 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported TSHA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $29.95M.
What is TSHA's Alpha Score?
How it works →Alpha Score of 22 reflects poor overall profile with weak momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TSHA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 4.40M | $29.95M | -1% |
| Millennium Management Israel Englander | 2.13M | $14.48M | -35% |
| Citadel Ken Griffin | 1.54M | $10.46M | +273% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are TSHA's key statistics?
Key statistics as of Nov 2, 2026
How does TSHA's valuation compare with the Healthcare sector?
| Metric | TSHA | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -780.33% | 3.60% | 175 |
| Return on equity | -56.19% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
TSHA price chart
Powered by TradingViewWhat does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.